The new questionnaire «Therapy Adherence Factor Scale»

DOI: https://doi.org/10.29296/25877305-2020-03-10
Download full text PDF
Issue: 
3
Year: 
2020

V. Isakov, Candidate of Medical Sciences; A. Kholkina; E. Zinkevich, Candidate of Pedagogical Sciences Saint Petersburg State Pediatric Medical University

High compliance is considered as one of the most important conditions for the efficiency of treatment. Confirmation of this can be seen by practitioners when using inpatients on an example; compensation for symptoms or recovery of the patient can be fully achieved by the healthcare staff’s monitoring of medical prescriptions under these conditions. Timely and adequate determination of the level of patient compliance will help to develop an effective treatment strategy for the period when the patient leaves the healthcare facility and is face-to-face with his/her diseases, which is especially important for patients with chronic diseases. Despite a certain abundance of indirect methods for diagnosing adherence to treatment, there are currently no methods for assessing factors influencing compliance. The designed questionnaire «Therapy adherence factor scale» used in patients who had undergone emergency intervention into the coronary arteries demonstrated satisfactory psychometric characteristics. Its use will assist investigators and practitioners to determine the factors that influence treatment adherence.

Keywords: 
treatment adherence
compliance
questionnaire
acute coronary syndrome



It appears your Web browser is not configured to display PDF files. Download adobe Acrobat или click here to download the PDF file.

References: 
  1. Haynes R., Taylor D., Sackett D. Compliance in Health Care / Baltimore, MD: The Johns Hopkins University Press, 1979; pp. 1–2.
  2. Royal Pharmaceutical Society of Great Britain. From Compliance to Concordance: Achieving Shared Goals in Medicine Taking / London: Royal Pharmaceutical Society, in partnership with Merck Sharp & Dohme, 1997; p. 55.
  3. Vrijens B., DeGeest S. A new taxonomy for describing and defining adherence to medications // Br. J. Clin. Pharmacol. – 2012; 73 (5): 691–705. DOI: 10.1111/j.1365-2125.2012.04167.x.
  4. Hahn S., Park J., Skinner E. et al. Development of the ASK-20 adherence barrier survey // Curr. Med. Res. Opin. – 2008; 24 (7): 2127–38. DOI: 10.1185/03007990802174769.
  5. Thompson K., Kulkarni J., Sergejew A. Reliability and validity of a new Medication Adherence Rating Scale (MARS) for the psychoses. // Schizophr. Res. – 2000; 42 (3): 241–7. DOI: 10.1016/S0920-9964(99)00130-9.
  6. Kim M., Hill M., Bone L. et al. Development and testing of the Hill-Bone Compliance to High Blood PressureTherapy Scale // Prog. Cardiovasc. Nurs. – 2000; 15 (3): 90–6. DOI: 10.1111/j.1751-7117.2000.tb00211.x.
  7. Morisky D., Green L., Levine D. Concurrent and predictive validity of a self-reported measure of medication adherence // Medical Care. – 1986; 24 (1): 67–74. DOI: 10.1097/00005650-198601000-00007.
  8. Morisky D., Ang A., Krousel-Wood M. et al. Predictive validity of a medication adherence measure in an outpatient setting // J. Clin. Hypertens. (Greenwich) – 2008; 10 (5): 348–54. DOI: 10.1111/j.1751-7176.2008.07572.x.
  9. Kisa A., Sabaté E., Nuño-Solinis R. Adherence to long-term therapies: evidence for action / Genève: Organisation mondiale de la Santé WHO, 2003; p. 198.
  10. Bjelland I., Dahl A., Haug T. et al. The validity of the Hospital Anxiety and Depression Scale. An updated literature review. // J. Psychosom. Res. – 2002; 52 (2): 69–77. DOI: S0022-3999(01)00296-3.
  11. Lukina Ju.V., Kutishenko N.P., Martsevich S.Ju. Priverzhennost' lecheniju: sovremennyj vzgljad na znakomuju problemu // Kardiovask. ter. i profilakt. – 2017; 16 (1): 91–5 [Lukina Yu., Kutishenko N., Martsevich S. Treatment adherence: modern view on a well known issue // Cardiovascular Therapy and Prevention. – 2017; 16 (1): 91–5 (in Russ.)] DOI: 10.15829/1728-8800-2017-1-91-95.
  12. Naletov A.V., V'junichenko Ju.S., Masjuta D.I. Roditel'skaja komplaentnost' i vlijajuschie na nee faktory pri lechenii detej s sindromom razdrazhennogo kishechnika // Pediatr. – 2018; 9 (2): 67–70 [Nalyotov A.V., Vunichenko Y.S., Masyuta D.I. Parental compliance and influences factors in treatment of children with irritable bowel syndrome // Pediatrician (St. Petersburg). – 2018; 9 (2): 67–70 (in Russ.)]. DOI: 10.17816/PED9267-70.
  13. Naletov A.V., Naletov S.V., Barinova A.S. i dr.. Effektivnost' antihelikobakternoj terapii v lechenii hronicheskoj gastroduodenal'noj patologii u detej pri razlichnyh urovnjah komplaentnosti // Pediatr. – 2018; 9 (4): 81–6 [Nalyotov A.V., Nalyotov S.V., Barinova A.S. et al. The effectiveness of anti-helicobacter therapy in the treatment of chronic gastroduodenal pathology in children with different levels of compliance // Pediatrician (St. Petersburg). – 2018; 9 (4): 81–6 (in Russ.)]. DOI: 10.17816/PED9481-86.
  14. Holkina A.A., Isakov V.A. Otsenka priverzhennosti lecheniju bol'nyh s metabolicheskim sindromom posle vmeshatel'stva na koronarnyh arterijah s pomosch'ju modifitsirovannogo oprosnika MMAS-8. Mat-ly VIII Ross. nauchno-prakt. kongr. «Metabolicheskij sindrom. Fundamental'nye i klinicheskie aspekty – ot teorii k praktike», 2018; s. 31–2 [Kholkina A.A., Isakov V.A. Otsenka priverzhennosti lecheniyu bol’nykh s metabolicheskim sindromom posle vmeshatel’stva na koronarnykh arteriyakh s pomoshch’yu modifitsirovannogo oprosnika MMAS-8. Mat-ly VIII Ross. nauchno-prakt. kongr. «Metabolicheskii sindrom. Fundamental’nye i klinicheskie aspekty – ot teorii k praktike», 2018; s. 31–2 (in Russ.)].